ST Germain D J Co. Inc. Decreases Stake in Novo Nordisk A/S (NYSE:NVO)

ST Germain D J Co. Inc. lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 1.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 79,961 shares of the company’s stock after selling 896 shares during the quarter. ST Germain D J Co. Inc.’s holdings in Novo Nordisk A/S were worth $6,878,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in NVO. Envestnet Asset Management Inc. boosted its position in Novo Nordisk A/S by 1.4% during the 2nd quarter. Envestnet Asset Management Inc. now owns 4,254,180 shares of the company’s stock valued at $607,242,000 after buying an additional 58,935 shares during the period. Raymond James & Associates raised its stake in shares of Novo Nordisk A/S by 1.0% during the third quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock valued at $419,939,000 after acquiring an additional 36,223 shares during the last quarter. Natixis Advisors LLC boosted its holdings in shares of Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after purchasing an additional 80,070 shares during the period. International Assets Investment Management LLC grew its stake in shares of Novo Nordisk A/S by 10,608.4% in the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after purchasing an additional 1,796,635 shares during the last quarter. Finally, DSM Capital Partners LLC increased its holdings in Novo Nordisk A/S by 257,816.0% during the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after purchasing an additional 1,593,303 shares during the period. Institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on NVO shares. BMO Capital Markets dropped their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Stock Up 1.1 %

Shares of NYSE:NVO traded up $0.91 during midday trading on Friday, reaching $86.55. The company’s stock had a trading volume of 2,646,449 shares, compared to its average volume of 6,717,778. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The firm has a 50 day moving average of $100.86 and a 200-day moving average of $119.79. The firm has a market capitalization of $388.40 billion, a P/E ratio of 28.01, a PEG ratio of 1.37 and a beta of 0.45. Novo Nordisk A/S has a 12-month low of $81.50 and a 12-month high of $148.15.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.